Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
Sponsor: Bernie Eigl
Summary
A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer. In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result. Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.
Official title: ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
260
Start Date
2021-01-11
Completion Date
2026-12-31
Last Updated
2025-12-15
Healthy Volunteers
No
Interventions
FGFR Testing
Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
Locations (7)
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
BC Cancer Agency
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CHU de Québec-Université Laval
Québec, Quebec, Canada